Background
John Classen held patents on methods related to vaccination scheduling and chronic immune-mediated disorders. Classen’s research had identified a correlation between the schedule of childhood vaccinations (specifically, the timing and number of vaccines given during certain developmental windows) and the risk of developing chronic immune-mediated disorders like type 1 diabetes. Classen’s patents claimed methods that: (1) analyzed data on vaccination schedules and disorder incidence to identify lower-risk schedules; and (2) in some claims, immunized a population according to the lower-risk schedule. Biogen IDEC challenged the patents as directed to unpatentable subject matter.
The district court found all claims patent-ineligible. Classen appealed. The case was decided before Alice v. CLS Bank but under the Bilski v. Kappos framework.
The Court’s Holding
The Federal Circuit affirmed in part and reversed in part. The court held that claims that merely required analyzing data and identifying a correlation (without requiring any further practical application) were patent-ineligible as directed to abstract mental processes or natural phenomena — essentially claiming the correlation itself. However, claims that required not just identifying the correlation but also immunizing a population according to the identified lower-risk schedule were patent-eligible — because the physical application step (actually immunizing) went beyond merely identifying and applying a natural correlation.
The decision drew an early distinction — later refined in Mayo, Alice, and Vanda — between claims that stop at identifying a natural correlation (patent-ineligible) and claims that require using that correlation as the basis for a concrete physical action (potentially patent-eligible).
Key Takeaways
- Method claims that require concrete physical actions based on a natural correlation — such as actually immunizing a population according to an identified lower-risk schedule — are more patent-eligible than claims that merely identify or apply the correlation without a physical implementation step.
- The Classen decision is an early pre-Alice data point in the diagnostic/therapeutic correlation patent eligibility saga — distinguishing between data analysis claims (ineligible) and action implementation claims (eligible) in a way that foreshadowed the Vanda Pharmaceuticals framework.
- Vaccination scheduling and public health intervention patents face significant § 101 scrutiny because the underlying correlations between intervention timing and health outcomes are natural phenomena — claims must require specific concrete actions based on those correlations, not merely the identification of the correlation.
- In the post-Mayo and post-Alice era, Classen’s holding has been largely superseded — the concrete action requirement alone may be insufficient under current doctrine if the action steps are conventional and the claim is directed primarily to the natural correlation.
Why It Matters
Classen Immunotherapies v. Biogen IDEC represented an early attempt by the Federal Circuit to draw a workable line between patent-eligible method claims that apply natural correlations through concrete physical actions and patent-ineligible claims that merely identify or observe natural phenomena. The case was decided in the post-Bilski but pre-Mayo environment and represents the state of § 101 law before the Supreme Court fundamentally restructured the framework in Mayo v. Prometheus (2012) and Alice v. CLS Bank (2014).
The decision is historically significant for showing how the Federal Circuit attempted to grapple with the diagnostic patent eligibility problem before the Supreme Court stepped in with a more categorical approach. The distinction between correlation-identification claims (ineligible) and correlation-implementation claims (eligible) — which Classen articulated — was later refined and partially adopted in Vanda Pharmaceuticals (2018), suggesting that the Classen intuition (though not its precise doctrinal framework) survived the Mayo/Alice era for method-of-treatment claims that require specific therapeutic actions.